New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression

• Main Author: Anna Dębińska
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Journal of Clinical Medicine
• Subjects: atopic dermatitis; skin barrier; filaggrin; biologicals; small molecule therapies
• Online Access: https://www.mdpi.com/2077-0383/10/11/2506

Atopic dermatitis (AD) is one of the most common chronic, inflammatory skin disorders with a complex etiology and a broad spectrum of clinical phenotypes. Despite its high prevalence and effect on the quality of life, safe and effective systemic therapies approved for long-term management of AD are limited. A better understanding of the pathogenesis of atopic dermatitis in recent years has contributed to the development of new therapeutic approaches that target specific pathophysiological pathways. Skin barrier dysfunction and immunological abnormalities are critical in the pathogenesis of AD. Recently, the importance of the downregulation of epidermal differentiation complex (EDC) molecules caused by external and internal stimuli has been extensively emphasized. The purpose of this review is to discuss the innovations in the therapy of atopic dermatitis, including biologics, small molecule therapies, and other drugs by highlighting regulatory mechanisms of skin barrier-related molecules, such as filaggrin (FLG) as a crucial pathway implicated in AD pathogenesis.